O’Brien, Emily C.
Raman, Sudha R.
Ellis, Alicia
Hammill, Bradley G.
Berdan, Lisa G.
Rorick, Tyrus
Janmohamed, Salim
Lampron, Zachary
Hernandez, Adrian F.
Curtis, Lesley H.
Funding for this research was provided by:
GlaxoSmithKline
Article History
Received: 15 June 2020
Accepted: 24 June 2021
First Online: 19 July 2021
Declarations
:
: The Duke Institutional Review Board (IRB) provided ethical oversight for the study. Informed consent was not necessary since the survey participants were site staff describing the trial recruitment processes, not providing protected health information.
: Not applicable.
: E.C.O.: grant support from Jansen, GSK, BMS, Sanofi, and NovartisS.R.: grant support from GSKA.E.: no relevant disclosuresB.G.H.: grant support from Abbott, GSK, Novartis, Amgen, St. Jude Medical, and Boston ScientificL.G.B.: no relevant disclosuresT.R.: no relevant disclosuresS.J.: employee and shareholder of GSKZ.L.: no relevant disclosuresA.F.H.: grant support from GSK, grants and personal fees from AstraZeneca and Merck, and personal fees from Boehringer Ingelheim outside the submitted workL.H.C.: grant support from GSK